T M Jensen1, D Vistisen1, T Fleming2, P P Nawroth2, P Rossing1, M E Jørgensen1,3, T Lauritzen4, A Sandbaek4, D R Witte4,5. 1. Steno Diabetes Center, Gentofte, Denmark. 2. Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany. 3. National Institute of Public Health, Southern Denmark University, Odense, Denmark. 4. Department of Public Health, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark. 5. Danish Diabetes Academy, Odense, Denmark.
Abstract
AIMS: The glycolysis-derived metabolite methylglyoxal has been linked to clinical microvascular complications, including diabetic nephropathy. We aimed to further investigate the hypothesis that methylglyoxal is involved in decline in renal function by assessing the associations between measures of renal function during a 6-year follow-up in 1481 people with screen-detected Type 2 diabetes, as part of the Danish arm of the ADDITION-Europe trial (ADDITION-DK). METHODS: Biobank serum samples collected at ADDITION-DK baseline (2001-2006) and follow-up (2009-2010) were used in the current analysis of methylglyoxal. We assessed cross-sectional baseline and longitudinal associations between methylglyoxal and urinary albumin-to-creatinine ratio (ACR) or estimated GFR (eGFR), and between methylglyoxal and categories of albuminuria or reduced eGFR. RESULTS:Baseline methylglyoxal was positively associated with ACR at baseline (12% higher ACR per doubling in methylglyoxal levels), and change in methylglyoxal during 6 years of follow-up was inversely associated with change in eGFR (-1.6 ml/min/1.73 m2 per doubling in methylglyoxal change), in models adjusted for age, sex, HbA1c , systolic blood pressure, anti-hypertensive treatment, LDL-cholesterol, lipid-lowering treatment, C-reactive protein and smoking. CONCLUSIONS: In a population of people with screen-detected Type 2 diabetes, we observed associations between methylglyoxal and markers of renal function: 6-year change in methylglyoxal was inversely associated with 6-year change in eGFR. Also, methylglyoxal at baseline was positively associated with ACR at baseline. Our study lends further support to a role for methylglyoxal in the pathogenesis of diabetic nephropathy.
RCT Entities:
AIMS: The glycolysis-derived metabolite methylglyoxal has been linked to clinical microvascular complications, including diabetic nephropathy. We aimed to further investigate the hypothesis that methylglyoxal is involved in decline in renal function by assessing the associations between measures of renal function during a 6-year follow-up in 1481 people with screen-detected Type 2 diabetes, as part of the Danish arm of the ADDITION-Europe trial (ADDITION-DK). METHODS: Biobank serum samples collected at ADDITION-DK baseline (2001-2006) and follow-up (2009-2010) were used in the current analysis of methylglyoxal. We assessed cross-sectional baseline and longitudinal associations between methylglyoxal and urinary albumin-to-creatinine ratio (ACR) or estimated GFR (eGFR), and between methylglyoxal and categories of albuminuria or reduced eGFR. RESULTS: Baseline methylglyoxal was positively associated with ACR at baseline (12% higher ACR per doubling in methylglyoxal levels), and change in methylglyoxal during 6 years of follow-up was inversely associated with change in eGFR (-1.6 ml/min/1.73 m2 per doubling in methylglyoxal change), in models adjusted for age, sex, HbA1c , systolic blood pressure, anti-hypertensive treatment, LDL-cholesterol, lipid-lowering treatment, C-reactive protein and smoking. CONCLUSIONS: In a population of people with screen-detected Type 2 diabetes, we observed associations between methylglyoxal and markers of renal function: 6-year change in methylglyoxal was inversely associated with 6-year change in eGFR. Also, methylglyoxal at baseline was positively associated with ACR at baseline. Our study lends further support to a role for methylglyoxal in the pathogenesis of diabetic nephropathy.
Authors: Sih Min Tan; Runa S J Lindblom; Mark Ziemann; Adrienne Laskowski; Cesare Granata; Matthew Snelson; Vicki Thallas-Bonke; Assam El-Osta; Carlos D Baeza-Garza; Stuart T Caldwell; Richard C Hartley; Thomas Krieg; Mark E Cooper; Michael P Murphy; Melinda T Coughlan Journal: Nutrients Date: 2021-04-25 Impact factor: 6.706
Authors: Sebastian Brings; Thomas Fleming; Marc Freichel; Martina U Muckenthaler; Stephan Herzig; Peter P Nawroth Journal: Int J Mol Sci Date: 2017-05-05 Impact factor: 5.923
Authors: Johanna Zemva; Christoph Andreas Fink; Thomas Henry Fleming; Leonard Schmidt; Anne Loft; Stephan Herzig; Robert André Knieß; Matthias Mayer; Bernd Bukau; Peter Paul Nawroth; Jens Tyedmers Journal: Redox Biol Date: 2017-08-12 Impact factor: 11.799
Authors: Irena Markova; Martina Hüttl; Olena Oliyarnyk; Tereza Kacerova; Martin Haluzik; Petr Kacer; Ondrej Seda; Hana Malinska Journal: Nutr Metab (Lond) Date: 2019-08-01 Impact factor: 4.169